Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages. AKB-6899 leads to stabilization of HIF-2α which induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 74.00 | |
5 mg | In stock | $ 178.00 | |
10 mg | In stock | $ 288.00 | |
25 mg | In stock | $ 485.00 | |
50 mg | In stock | $ 693.00 | |
100 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 197.00 |
Description | AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages. AKB-6899 leads to stabilization of HIF-2α which induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth. |
In vitro | In murine bone marrow-derived macrophages, AKB-6899 (10 μM; 24 hours) increases the levels of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 shows no effect on HIF-1α accumulation or VEGF production[1]. |
In vivo | In C57BL/6 mice injected with B16F10 murine melanoma cells, AKB-6899 (17.5 mg/kg; i.p.) significantly reduces tumor growth[1]. |
Synonyms | AKB6899 |
Molecular Weight | 290.25 |
Formula | C14H11FN2O4 |
CAS No. | 1007377-55-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (327.30 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AKB-6899 1007377-55-0 Angiogenesis Chromatin/Epigenetic Metabolism Tyrosine Kinase/Adaptors HIF VEGFR HIF/HIF Prolyl-Hydroxylase antiangiogenic Inhibitor antitumor AKB 6899 HIF-PH HIF-2α sVEGFR-1 HIFs AKB6899 inhibit Hypoxia-inducible factors PHD3 inhibitor